New regulations proposed by the California state Department of Managed Health Care (DMHC) that are expected to be implemented by the end of this year would require HMOs in California to cover all medically necessary prescription drugs, even if they are excluded from a plan's formulary.
New regulations proposed by the California state Department of Managed Health Care (DMHC) that are expected to be implemented by the end of this year would require HMOs in California to cover all medically necessary prescription drugs, even if they are excluded from a plan's formulary.
Under the proposed regulations, HMOs would not be required to pay for prescriptions if comparable OTC drugs could be purchased, but HMOs would be required to reimburse patients if the OTC drugs are ineffective.
Percentage copayments would be capped at 50% of the drug cost. Drugs that would not be covered include those used for cosmetic purposes, sexual performance, and weight loss.
DMHC's regulations, which were provided for public comment in January and are scheduled to undergo a second public comment period, were mandated by legislation passed in 2002.
According to Cindy Ehnes, director, DMHC: "California is now the only state in the nation to have clear, comprehensive standards for consumers to have access to medically necessary prescription drugs. There will be no doubt in a patient's mind as to which drugs are covered."
SOURCES California Department of Managed Healthcare website. Department of Managed Care announces new prescription drug protections for HMO consumers [press release]. Available at: http://www.hmohelp.ca.gov/. Accessed April 25, 2005.
American Medical Association website. California HMOs facing drug access rule [press release]. Available at: http://www.ama-assn.org/amednews/2005/01/24/bisb0124.htm . Accessed April 25, 2005.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More